trending Market Intelligence /marketintelligence/en/news-insights/trending/3Opc2U-irQwx5TreESOArA2 content esgSubNav
In This List

Jury favors Johnson & Johnson, Bayer in 2nd trial over blood-thinning drug

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Jury favors Johnson & Johnson, Bayer in 2nd trial over blood-thinning drug

A New Orleans jury ruled that Johnson & Johnson and Bayer AG are not at fault for the death of a woman who had taken blood-thinning drug Xarelto, Bloomberg News reported.

The family of 67-year-old Sharyn Orr blamed her death on the drug, which was jointly developed by the two companies. Orr began taking Xarelto in February 2014 and died in May 2015, following a massive brain hemorrhage.

The decision is the second straight win for the companies, following an earlier decision in May. There are still more than 18,000 patient lawsuits over the drug. U.S. Food and Drug Administration reports indicate that Xarelto has been linked to at least 370 deaths, according to Bloomberg News.

The next trial is scheduled for Aug. 7 in federal court in Jackson, Miss.